Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002–2018 Empirical/Pre-emptive Approach

[1]  M. Konopleva,et al.  Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Yeon Joo Lee,et al.  A single center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplant (HCT). , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  J. Perfect,et al.  Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Esteve,et al.  Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease , 2019, Blood.

[5]  E. Barragán,et al.  Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis , 2019, Annals of Hematology.

[6]  Maheshwari Patel,et al.  Study , 2019, Definitions.

[7]  B. Noble,et al.  Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic-cell transplant recipients. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  L. Pagano,et al.  ‘Real-life’ analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study , 2019, The Journal of antimicrobial chemotherapy.

[9]  T. Rogers,et al.  Defining standards of CARE for invasive fungal diseases in adult haematology patients: antifungal prophylaxis versus treatment. , 2019, Journal of Antimicrobial Chemotherapy.

[10]  J. Steinmann,et al.  Airborne Aspergillus fumigatus spore concentration during demolition of a building on a hospital site, and patient risk determination for invasive aspergillosis including azole resistance. , 2018, The Journal of hospital infection.

[11]  P. Ljungman,et al.  European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. , 2018, The Journal of antimicrobial chemotherapy.

[12]  L. Pagano,et al.  Prophylaxis for aspergillosis in patients with haematological malignancies: pros and cons , 2018, Expert review of anti-infective therapy.

[13]  M. Tormo,et al.  Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high‐risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real‐world comparison , 2018, Mycoses.

[14]  M. Ouellette,et al.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. , 2017, The Lancet. Infectious diseases.

[15]  S. Iacobelli,et al.  Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  L. Pagano,et al.  Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. , 2017, Blood reviews.

[17]  L. Pagano,et al.  Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? , 2017, Medical mycology.

[18]  M. Hellmich,et al.  Outcome of empirical or targeted antifungal therapy after antifungal prophylaxis in febrile neutropenia , 2016, Annals of Hematology.

[19]  J. Chen,et al.  Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy , 2016, Medicine.

[20]  B. Ko,et al.  High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan , 2015, PloS one.

[21]  V. Pavone,et al.  Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) , 2015, Haematologica.

[22]  F. Fernández‐Avilés,et al.  Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time , 2015, Bone Marrow Transplantation.

[23]  M. Cuenca‐Estrella,et al.  Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  J. Belmonte,et al.  Environmental variables associated with an increased risk of invasive aspergillosis. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[25]  Anne Sonet,et al.  A European prospective invasive mould disease audit , 2014 .

[26]  L. Pagano,et al.  Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  J. Esteve,et al.  A scoring system to predict the risk of death during induction with anthracycline plus cytarabine‐based chemotherapy in patients with de novo acute myeloid leukemia , 2012, Cancer.

[28]  P. Vanhems,et al.  Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[29]  C. Gudiol,et al.  Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation , 2011, Bone Marrow Transplantation.

[30]  J. Briones,et al.  Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution , 2011, Bone Marrow Transplantation.

[31]  Giuseppe Leone,et al.  Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study , 2010, Haematologica.

[32]  M. Shivaprakash,et al.  An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. , 2009, The Journal of antimicrobial chemotherapy.

[33]  J. Sierra,et al.  Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Single‐center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes , 2009, American journal of hematology/oncology.

[34]  T. Franquet,et al.  Correlation between high-resolution computed tomography and galactomannan antigenemia in adult hematologic patients at risk for invasive aspergillosis. , 2009, European journal of radiology.

[35]  J. Briones,et al.  Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT , 2009, Bone Marrow Transplantation.

[36]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  C. Viscoli,et al.  Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin , 2006, British journal of haematology.

[38]  N. Villamor,et al.  Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)] , 2006, Leukemia.

[39]  J. Sierra,et al.  Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies , 2005, Leukemia & lymphoma.

[40]  J. Sierra,et al.  Low‐dose amphotericin b lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies – a randomized, controlled trial , 2004, European journal of haematology.

[41]  R. Martino,et al.  Invasive fungal infections in hematology: new trends , 2002, Annals of Hematology.

[42]  T. Franquet,et al.  Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. , 2002, Haematologica.

[43]  T. Franquet,et al.  Bronchoscopy guided by high-resolution computed tomography for the diagnosis of pulmonary infections in patients with hematologic malignancies and normal plain chest X-ray. , 2000, Haematologica.

[44]  R. Martino,et al.  Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies. , 1999, The Journal of antimicrobial chemotherapy.